FDA
-
-
-
-
-
-
-
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025
-
-
-
-
-
-
-
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
-
-
-
-
-
-
-
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
-
-
-
-
-
-
-
Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Tenaya Therapeutics (TNYA) Announes FDA Orphan Drug Designation for
-
-
-
-
-
-
-
Tenaya Therapeutics (TNYA) Reports Publication of Preclinical Data Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

